Treatments for Nail Psoriasis: A Systematic Review by the GRAPPA Nail Psoriasis Work Group

Nail involvement in psoriatic diseases causes significant physical and functional disabilities. Evaluating, measuring, and treating nail involvement is important in improving the health outcomes and quality of life among patients with psoriasis and psoriatic arthritis (PsA). We performed a systematic analysis of the literature on nail psoriasis to help inform an update of treatment recommendations by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).

[1]  Y. Wasfi,et al.  Ustekinumab improves nail disease in patients with moderate‐to‐severe psoriasis: results from PHOENIX 1 , 2014, The British journal of dermatology.

[2]  D. M. van der Heijde,et al.  Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) , 2013, Annals of the rheumatic diseases.

[3]  M. Goldust,et al.  Clinical Trial Study in the Treatment of Nail Psoriasis with Pulsed Dye Laser. , 2013, Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology.

[4]  A. Aktürk,et al.  Effectiveness of systemic treatment agents on psoriatic nails: a comparative study. , 2013, Journal of drugs in dermatology : JDD.

[5]  A. H. Erbil,et al.  Treatment of nail psoriasis with tumor necrosis factor‐alpha blocker agents: An open‐label, unblinded, comparative study , 2013, The Journal of dermatology.

[6]  M. D’Agostino,et al.  Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open‐label study , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  D. Sotiriadis,et al.  Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study , 2013, The Journal of dermatological treatment.

[8]  E. Berardesca,et al.  A 24‐week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis , 2013, The British journal of dermatology.

[9]  D. Sotiriadis,et al.  Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study , 2013, The Journal of dermatological treatment.

[10]  S. Chimenti,et al.  TNF-α antagonists and nail psoriasis: an open, 24-week, prospective cohort study in adult patients with psoriasis , 2013, Expert opinion on biological therapy.

[11]  K. Pavelka,et al.  Leflunomide in psoriatic arthritis: Results from a large European prospective observational study , 2013, Arthritis care & research.

[12]  A. Tosti,et al.  Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients , 2013, International journal of dermatology.

[13]  Yu-Chen Huang,et al.  Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease: A single‐blind, intrapatient left‐to‐right controlled study , 2013, Lasers in surgery and medicine.

[14]  F. Llambi,et al.  Nail psoriasis: treatment with tazarotene 0.1% hydrophilic ointment. , 2012, Actas dermo-sifiliograficas.

[15]  Mahboob Rahman,et al.  Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. , 2012, Arthritis and rheumatism.

[16]  M. Sánchez-Regaña,et al.  Efficacy of adalimumab in the treatment of psoriasis: A retrospective study of 15 patients in daily practice , 2012, The Journal of dermatological treatment.

[17]  K. Chanprapaph,et al.  The effect of different pulse durations in the treatment of nail psoriasis with 595-nm pulsed dye laser: a randomized, double-blind, intrapatient left-to-right study. , 2012, Journal of the American Academy of Dermatology.

[18]  Subhashis Banerjee,et al.  Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. , 2012, The New England journal of medicine.

[19]  H. Nakagawa,et al.  Efficacy and safety of ustekinumab in Japanese patients with moderate‐to‐severe plaque‐type psoriasis: Long‐term results from a phase 2/3 clinical trial , 2012, The Journal of dermatology.

[20]  G. Kingsley,et al.  A randomized placebo-controlled trial of methotrexate in psoriatic arthritis , 2012, Rheumatology.

[21]  D. Rigopoulos,et al.  Efficacy of Ustekinumab in Nail Psoriasis and Improvement in Nail-Associated Quality of Life in a Population Treated with Ustekinumab for Cutaneous Psoriasis: An Open Prospective Unblinded Study , 2011, Dermatology.

[22]  P. Sfikakis,et al.  Adalimumab or Cyclosporine as Monotherapy and in Combination in Severe Psoriatic Arthritis: Results from a Prospective 12-month Nonrandomized Unblinded Clinical Trial , 2011, The Journal of Rheumatology.

[23]  J. Ortonne,et al.  A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. , 2011, The New England journal of medicine.

[24]  S. Bodur,et al.  Evaluation of the efficacy of methotrexate and cyclosporine therapies on psoriatic nails: a one‐blind, randomized study , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[25]  M. Alsina-Gibert,et al.  Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy) , 2011 .

[26]  T. Lotti,et al.  Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[27]  H. Nakagawa,et al.  Long‐term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma , 2011, The Journal of dermatology.

[28]  K. Papp,et al.  Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. , 2011, Archives of dermatology.

[29]  H. Nakagawa,et al.  Japanese Ustekinumab Study. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: longterm results from a phase II/III clinical trial , 2011 .

[30]  J. Saurat,et al.  Skin and Nail Responses after 1 Year of Infliximab Therapy in Patients with Moderate-to-Severe Psoriasis: A Retrospective Analysis of the EXPRESS Trial , 2010, Dermatology.

[31]  H. Nakagawa,et al.  Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. , 2010, Journal of dermatological science.

[32]  H. Kupper,et al.  Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy , 2010, Arthritis research & therapy.

[33]  A. Katsambas,et al.  Treatment of nail psoriasis with adalimumab: an open label unblinded study , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[34]  P. Goupille,et al.  Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions , 2009, Annals of the rheumatic diseases.

[35]  J. Lambert,et al.  Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate‐to‐severe psoriasis , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[36]  D. Gladman,et al.  Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. , 2009, Arthritis and rheumatism.

[37]  B. Piraccini,et al.  Evaluation of the efficacy of acitretin therapy for nail psoriasis. , 2009, Archives of dermatology.

[38]  C. R. Daniel,et al.  Treatment of Nail Psoriasis with a Two-Compound Formulation of Calcipotriol plus Betamethasone Dipropionate Ointment , 2009, Dermatology.

[39]  B. Thiers.  Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study , 2009 .

[40]  F. Nestle,et al.  Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. , 2008, Journal of the American Academy of Dermatology.

[41]  T. Tzung,et al.  Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. , 2008, Acta dermato-venereologica.

[42]  O. Ishikawa,et al.  Successful treatment of psoriatic nails with low-dose cyclosporine administration. , 2007, European journal of dermatology : EJD.

[43]  A. Kavanaugh,et al.  Therapies for psoriatic nail disease. A systematic review. , 2006, The Journal of rheumatology.